Anti-Therapeutic Action: drug interactions

Clinical Significance and Therapeutic Challenges of Scedosporium spp. and Lomentospora prolificans Isolates in a Single-Center Cohort of Lung Transplant Recipients

mycolabadmin

This study examined rare but serious fungal infections caused by Scedosporium and Lomentospora in lung transplant patients. Of 576 transplant recipients, 11 (2%) developed these infections, which are difficult to treat due to natural resistance to most antifungal medications. The infection type greatly influenced outcomes, with disseminated Lomentospora infections causing 100% mortality despite treatment. The research highlights the urgent need for new diagnostic methods and more effective antifungal drugs to combat these emerging pathogens.

Read More »

Clinical Significance and Therapeutic Challenges of Scedosporium spp. and Lomentospora prolificans Isolates in a Single-Center Cohort of Lung Transplant Recipients

mycolabadmin

This study examined dangerous fungal infections caused by Scedosporium and Lomentospora species in lung transplant patients at a Spanish hospital. Researchers found these infections were uncommon but very serious, with high death rates especially from the Lomentospora type. Current antifungal drugs often don’t work well against these fungi, highlighting the need for better treatment options.

Read More »

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A 28-year-old woman developed a serious fungal infection (histoplasmosis) after dental surgery that was initially misdiagnosed as a bacterial infection. Although she was treated with an antifungal medication called itraconazole, her condition worsened with larger lung lesions appearing. When switched to a stronger intravenous antifungal called liposomal amphotericin B, she rapidly improved and fully recovered, demonstrating the importance of adjusting treatment when patients don’t respond as expected.

Read More »

Low Antigen Titre Disseminated Cryptococcosis in Immunocompromised Hosts: Two Challenging Case Reports

mycolabadmin

Two patients with weakened immune systems developed serious fungal blood infections from Cryptococcus despite having unusually low levels of fungal markers in their blood. One was a kidney transplant patient and the other had HIV. Neither showed signs of brain infection, which is unusual for this disease. Both were successfully treated with aggressive antifungal medications once blood cultures confirmed the disseminated infection.

Read More »

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial

mycolabadmin

Researchers surveyed chronic pain patients about their willingness to participate in a trial testing psilocybin (a compound from magic mushrooms) as a pain treatment. About 77% of patients were interested in participating. Interestingly, patients who had previously used psychedelics were much more willing to join the trial. Common reasons for wanting to participate included needing new pain treatments, while concerns about side effects and practical difficulties like attending multiple appointments discouraged others.

Read More »
Scroll to Top